Application of KREMEN1 and/or ASGR1 as drug target in treatment of SARS-CoV-2 infection
The invention discloses an application of KREMEN1 and/or ASGR1 as a drug target in the treatment of SARS-CoV-2 infection. Researches find that the transient expression of the ASGR1 and/or KREMEN1 can cause the invasion of the SARS-CoV-2, and the SARS-CoV-2 infection can be effectively prevented or treated by inhibiting the binding of the S protein of the SARS-CoV-2 and the ASGR1 and/or KREMEN1, so that the invention provides a new thought for the treatment of the SARS-CoV-2 infection..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 31. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LUO MIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-12-31, Last update posted on www.tib.eu: 2023-06-15, Last updated: 2023-06-23 |
|---|
| Patentnummer: |
CN113862326 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013093533 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013093533 | ||
| 003 | DE-627 | ||
| 005 | 20230623184819.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013093533 | ||
| 035 | |a (EPA)CN113862326 | ||
| 035 | |a (EPA)78989613 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LUO MIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of KREMEN1 and/or ASGR1 as drug target in treatment of SARS-CoV-2 infection |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-12-31, Last update posted on www.tib.eu: 2023-06-15, Last updated: 2023-06-23 | ||
| 520 | |a The invention discloses an application of KREMEN1 and/or ASGR1 as a drug target in the treatment of SARS-CoV-2 infection. Researches find that the transient expression of the ASGR1 and/or KREMEN1 can cause the invasion of the SARS-CoV-2, and the SARS-CoV-2 infection can be effectively prevented or treated by inhibiting the binding of the S protein of the SARS-CoV-2 and the ASGR1 and/or KREMEN1, so that the invention provides a new thought for the treatment of the SARS-CoV-2 infection. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
| 650 | 4 | |a tec | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a LU ZHIGANG |4 aut | |
| 700 | 0 | |a ZHAO YUN |4 aut | |
| 700 | 0 | |a GAO HAI |4 aut | |
| 700 | 0 | |a XIE YOUHUA |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 31. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/78989613/publication/CN113862326A1?q=CN113862326 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2021 |b 31 |c 12 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 31 |c 12 | ||